Summary of Significant Accounting Policies - Schedule of Percentage of Revenues and Accounts Receivables from Customers (Details) - Customer Concentration Risk |
12 Months Ended | |
|---|---|---|
Dec. 31, 2024 |
Dec. 31, 2023 |
|
| Revenue | Natera Inc. | ||
| Summary Of Significant Accounting Policies [Line Items] | ||
| Concentration risk percentage | 30.00% | 43.00% |
| Revenue | VA MVP | ||
| Summary Of Significant Accounting Policies [Line Items] | ||
| Concentration risk percentage | 13.00% | |
| Revenue | Moderna, Inc. | ||
| Summary Of Significant Accounting Policies [Line Items] | ||
| Concentration risk percentage | 28.00% | |
| Accounts Receivable | Natera Inc. | ||
| Summary Of Significant Accounting Policies [Line Items] | ||
| Concentration risk percentage | 13.00% | 36.00% |
| Accounts Receivable | Merck & Co., Inc. | ||
| Summary Of Significant Accounting Policies [Line Items] | ||
| Concentration risk percentage | 31.00% | |
| Accounts Receivable | Pfizer Inc. | ||
| Summary Of Significant Accounting Policies [Line Items] | ||
| Concentration risk percentage | 25.00% | |